Literature DB >> 12893368

Clinical significance of allelotype profiling for urothelial carcinoma.

Tzong-Shin Tzai1, Helen Hai-Wen Chen, Shih-Huang Chan, Chung-Liang Ho, Yuh-Shyan Tsai, Hong-Lin Cheng, Yuan-Chang Dai, Johnny Shinn-Nan Lin, Wen-Hong Yang, Nan-Haw Chow.   

Abstract

OBJECTIVES: To perform a global loss of heterozygosity (LOH) analysis on a cohort of urothelial carcinoma to investigate the clinical implication of specific chromosomal loss. Allelic deletions detected as LOH have been used to study the markers for carcinogenesis.
METHODS: We examined the allelic loss on 14 chromosomal regions in a total of 71 cases of urothelial carcinoma. The results were analyzed in relation to biologic indicators of urothelial carcinoma and the clinical outcome with a mean follow-up of 101 months.
RESULTS: The incidence of LOH in order of frequency was 9p (54.9%), 9q (49.3%), 13q (40.8%), 14q (40.8%), 10q (39.4%), 17p (39.4%), 8p (38.0%), 21q (36.6%), 11p (31.0%), 18q (23.9%), 4q (21.1%), 3p (16.9%), 6q (14.1%), and 1q (8.5%). Positive association with one of the indicators was observed in 3p, 9p, 9q, 10q, 14q, and 18q. The chromosomes that correlated with two biologic indicators were 4q, 6q, 11p, 17p, and 21q. Univariate analysis found that patients having combined 9p and 14q deleted tumors had particularly poor long-term survival compared with those with other patterns of chromosomal alterations (P = 0.01). In the multivariate model, nonpapillary tumors had a greater risk of recurrence, and stage classification was the only important indicator in predicting patient survival (P = 0.04).
CONCLUSIONS: LOH assessment does not provide independent prognostic value compared with stage classification. However, chromosomes 4q, 6q, 9p, 11p, 14q, 17p, and 21q may harbor important tumor suppressor genes involved in the progression of urothelial carcinogenesis.

Entities:  

Mesh:

Year:  2003        PMID: 12893368     DOI: 10.1016/s0090-4295(03)00344-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Prevalence and spectrum of microsatellite alterations in nonmuscle invasive bladder cancers.

Authors:  Guillaume Legrand; Hany Soliman; Francis Dubosq; Jérôme Vérine; François Desgrandchamps; Hugues de Thé; Pierre Mongiat-Artus; Guillaume Ploussard
Journal:  Am J Cancer Res       Date:  2011-04-05       Impact factor: 6.166

2.  Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.

Authors:  Simion Chiosea; Elena Jelezcova; Uma Chandran; Marie Acquafondata; Teresa McHale; Robert W Sobol; Rajiv Dhir
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

3.  Up-regulated Dicer expression in patients with cutaneous melanoma.

Authors:  Zhihai Ma; Helen Swede; David Cassarino; Elizabeth Fleming; Andrew Fire; Soheil S Dadras
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

4.  DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection.

Authors:  Priscilla D Negraes; Francine P Favaro; João Lauro V Camargo; Maria Luiza C S Oliveira; José Goldberg; Cláudia A Rainho; Daisy M F Salvadori
Journal:  BMC Cancer       Date:  2008-08-14       Impact factor: 4.430

5.  The role of chemotherapy in upper tract urothelial carcinoma.

Authors:  Peter H O'Donnell; Walter M Stadler
Journal:  Adv Urol       Date:  2009-01-26

6.  Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer.

Authors:  Ding-Zuan Zhang; Kin-Mang Lau; Eddie S Y Chan; Gang Wang; Cheuk-Chun Szeto; Kenneth Wong; Richard K W Choy; Chi-Fai Ng
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.